■■ Pharmaceutical Patient Assistance Programs: Don't Look a Gift Horse in the Mouth or There's No Such Thing as aFree Lunch
The affordability of prescription drugs is amajor problem for many Americans. For at least the last decade, almost 17% of the under-65-years population-approximately 41 million individualshas been without health insurance. 1 In addition, as ubstantial number of consumers who arei nsured at some point during any given year areu ninsured at other times during the year. Families USA reported that about 81.8 million Americans under the age of 65 lacked health insurance at some point during the 2003-2004 period. 2 They further reported that two thirds of this number wereu ninsured for 6o rm orem onths and 51% were uninsured for 9o rm orem onths. 2 Gupta et al. have reported that about 12.5% of working age (18-64 years) adults in the United States experienced periods wherethey lacked insurance for prescription drugs during 2000. 3 This was in addition to the 21.5% that lacked prescription drug insurance for all of 2000. 3 Even consumers who arec overed by prescription drug insurance may have trouble affording prescription drugs. The Center for Studying Health System Change reported that, during 2003, 15.2% of privately insured working age adults (those aged 18-64 years) with chronic health conditions failed to get needed prescription medicines at least once in the previous 12 months because they could not affordt hem. 4 This amounted to 5.5 million adults who had jobs and insurance and yet could not affordneeded medications at some time during the year.Piette et al. have reported that 17% of anational sample of individuals aged 50 years and older who took medication for diabetes, depression, heart problems, hypertension, or high cholesterol reported taking "less of their medication in the prior 12 months because of the cost." 5 Affordability of prescription drugs is ap roblem for many insured patients in part because of increased use of tiered formularies and increased patient cost sharing 4 as well as the higher prices of new prescription products. The Kaiser Family Foundation reports that the average community pharmacy prescription price increased from $28.67 in 1994 to $68.26 in 2006. These trends suggest that the problem of affordability of prescription drugs is likely to grow in the foreseeable future.
Affordability is an especially significant problem for those on specialty pharmaceuticals. These products ares ubstantially moreexpensive than traditional, chemical-based products. The Express Scripts Drug Trend Report indicates that the average cost of aprescription for aspecialty product in 2006 was $1,454. 7 Patients typically filled between 4and 10 prescriptions per year for each specialty product prescribed for them. The Wall Street Journal reported that the price for cancer treatment with specialty products can range from $36,000 to $56,000 per patient. 8 Some insurers have created specialty copayment tiers in pharmacy benefits for these products that requirep atient coinsurance of 20% to 50%. 9 Even though coinsurance payments in these programs areo ften limited by out-of-pocket payment limits of $100 to $250 per prescription fill, these coinsurance amounts may exceed the ability to pay for many health plan members. Further,t he high cost of most specialty products, many for chronic conditions, contributes to total medical costs that can push patients over insurance policy life-time maximum amounts, leaving them without insurance coverage. Ar ecent Wall Street Journal article noted that the cost of treatment with Myozyme, a specialty drug used to treat ar aree nzyme disorder,m ay be as much as $300,000 per year. 10 Pharmaceutical company patient assistance programs (PAPs) offer one potential solution to the problem of affordability of prescription drugs. These programs provide pharmaceuticals to medically indigent patients for free or for substantially reduced prices. The Pharmaceutical Research and Manufacturers Association (PhRMA) indicates that these programs provided $5 billion worth of free drugs to needy consumers in 2005. 11 A number of studies have documented the savings generated by these programs for consumers, health centers, and hospitals. For example, Sarrafizadeh et al. reported that aprivate ambulatoryc arec linic in upstate New York saved $48,143 by using patient assistance programs for 44 patients during a1-year study period. 12 Johnson indicated that the H. Lee Moffitt Cancer Center saved $1.5 million in 2006 as ar esult of using PAPs for indigent patients. 13 Hotchkiss reported savings of $7,000 per month in a state psychiatric facility that served about 48 patients each month. 14 Chisholm et al. indicated that use of PAPs resulted in cost avoidance of between $69,000 and $125,000 in atransplant clinic in auniversity teaching hospital for the 1998 calendar year. 15 Coleman et al. reported net savings of $57,000 over 6months for indigent inpatients in aConnecticut hospital. 16 As Clay et al. documented in an article in ap revious issue of JMCP, PAPs aren ot without costs. 17 While the drug product may be provided free of charge, the health carep rovider or organization realizes substantial costs in applying for and distributing the products. An application must be submitted for each product requested. Different manufacturers have different application processes, many of whicha re complicateda nd lengthy. Some applications requiredocumentation of patient need or requirethat documentation includes the patient' st ax returns. While some manufacturers allow for refills, many requireanew application for each refill. Application processes may change without notice at any time. Pharmacists, social workers, and/or trained clerical personnel aretypically involved in completing application forms and applications always requiresome degree of physician involvement. In anational survey of safety net clinics, Duke et al. reported that the most common reason for not using PAPs was that they were "too time consuming and complex," 18 followed closely by "unrealistic income documentation requirements for indigent patients." 18 Large providers, such as pharmacies in university teaching hospitals, may have fewer problems administering PAPs because their large scale may allow the use of bulk replacement programs. These allow pharmacies to dispense PAPp roducts to indigent patients without completing the manufacturer application process. Most hospitals have financial counselors or financial assistance specialists who determine patients' insurance status and ability to pay their hospital charges. These same financial assistance specialists can be used to determine whether patients qualify for PAPs. Once individuals ared eemed to be qualified by the financial counselor,t he pharmacy dispenses their PAP medications and notes that the medications weredispensed for aP AP patient. At the end of each month (or quarter,depending in the manufacturer' sp olicy), the pharmacy determines the quantity of each manufacturer' sdrugs dispensed to PAPpatients and sends ar eport with this information to the manufacturer. The manufacturer then ships the pharmacy as ufficient quantity of each product to replace what was dispensed to PAPpatients.
The costs that providers, institutions, and patients incur in using PAPs have not been well documented. Most of the available research has been limited to estimation of the short-term, direct costs of operating PAPs from the health carei nstitution' sp erspective. [14] [15] [16] 18, 19 Most researchers have focused on the costs of pharmacists, technicians, and other employees-such as social workers or patient registration technicians-employed to manage the process of applying for and dispensing PAPd rugs. For the most part, these studies have not included valuation of physician' st ime, overhead costs to the institution, or patients' time. However,the magnitude of savings that have been attributed to PAPs suggest that they would be cost-effective even after consideration of these additional costs. In one of the most comprehensive cost studies, Richardson and Basskin surveyed anational sample of safety net clinics and hospitals in 2000. 20 They calculated the net benefit of PAPs by subtracting the cost of providing the program from the total value of medications received through the programs; the 340B acquisition prices wereused to value the medications. Costs included labor,equipment, and miscellaneous (i.e., postage and mailing). The median annual net benefit for their sample ranged from $48,000 for clinics with outpatient medication budgets under $500,000 to $877,000 for hospitals with outpatient medication budgets over $500,000.
PAPs may also be associated with costs that arelonger-term and moredifficult to quantify.P APs operated by the research-intensive pharmaceutical companies, which operate the great majority of PAPs, area lmost always restricted to expensive, patented, brandname products. Consequently,physicians who treat medically indigent patients frequently face the choice of providing a" free" PAP drug or an equally effective generic alternative. While the PAPdrug is cheaper in the short run, it may be moreexpensive to both the health caresystem and the patient in the long run. In the short run, the "free" drug solves the physician' sproblem of providing therapy to apatient unable to pay for needed prescriptions. In the long run, however,P APs may increase costs.
First, the use of PAPd rugs may disrupt the formulary process. 21 Physicians may become accustomed to using expensive, non-formularyP AP products rather than the generally less expensive formularyp roducts. To the extent that this practice spills over to prescribing for non-indigent patients, health system costs increase. If, or when, PAPc overage ends, the patient faces paying for am uch moree xpensive product or being switched to another product. Switching products is also not without costs; patients may be required to make additional physician visits and undergo additional laboratoryt ests to be stabilized on the new drug. Similarly,i fa nu ninsured patient gains insurance coverage, the insurance company must either pay for am oree xpensive product or pay to have the patient switched to anew product.
Second, PAPs may also deflect attention from finding am ore comprehensive solution to the problem of affordable drugs. The existence of PAPs supports the illusion that affordability of prescription drugs is not ap roblem because therei sam echanism through which all patients, regardless of income, can get the drugs they need. In fact, thereare large numbers of consumers who are unable to affordneeded prescription drugs and who areineligible for or unawareofP APs. The Partnershipfor Prescription Assistance program, which includes but is not restricted to pharmaceutical company PAPs, provided prescription drugs for morethan 3.6 million consumers in its first 2years of existence, from April 2005 to April 2007. 11 While this is asubstantial number of consumers, it is af raction of the 81.8 million without insurance at sometime during that period. 2 Further,itisasmaller number than the 5.5 million working and privately insured consumers who did not get needed medicines due to cost concerns during 2003. 4 Finally,PAP drugs, like all products and services, cannot be provided free of cost. Their cost is ultimately borne by cash-paying consumers in the form of higher drug prices and by insured consumers in the form of higher insurance premiums, deductibles, and copayments. PAPd rugs areb est used as part of ac omprehensive program of therapeutic selection in which PAPs areone component of amultifaceted strategy to improve access to medications, such as the pharmacist-directed intervention described previously in JMCP by Stebbins et al. for one large medical group California. 22 How one views PAPs depends on one' sperspective. In the short run, they provide billions of dollars of prescription drugs to consumers who might otherwise be denied needed drug therapy.Inthe long run, PAPs may actually exacerbate the problem of access to prescription drugs by deflecting concernabout the issue of affordability and by contributing to the use of higher-cost drugs. Despite their long-term costs, it seems likely that PAPs will continue to be necessarya nd heavily-used until am orec omprehensive solution to the problem of prescription drug affordability is developed. 
